Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

The Lancet Diabetes & Endocrinology, Journal Year: 2019, Volume and Issue: 7(9), P. 715 - 725

Published: July 10, 2019

Language: Английский

---

Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

Gastroenterology, Journal Year: 2020, Volume and Issue: 158(7), P. 1851 - 1864

Published: Feb. 13, 2020

Language: Английский

---

Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?

Journal of Hepatology, Journal Year: 2017, Volume and Issue: 68(2), P. 335 - 352

Published: Nov. 6, 2017

Language: Английский

---

Complications, morbidity and mortality of nonalcoholic fatty liver disease

Metabolism, Journal Year: 2020, Volume and Issue: 111, P. 154170 - 154170

Published: Jan. 30, 2020

Language: Английский

---

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus

Nature Reviews Endocrinology, Journal Year: 2017, Volume and Issue: 14(2), P. 99 - 114

Published: Dec. 29, 2017

Language: Английский

---

NAFLD as a driver of chronic kidney disease

Journal of Hepatology, Journal Year: 2020, Volume and Issue: 72(4), P. 785 - 801

Published: Feb. 12, 2020

Language: Английский

---

Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis

Metabolism, Journal Year: 2017, Volume and Issue: 79, P. 64 - 76

Published: Nov. 11, 2017

Language: Английский

---

Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

Gut, Journal Year: 2020, Volume and Issue: 71(1), P. 156 - 162

Published: Dec. 10, 2020

Objective Studies reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased risk of chronic kidney (CKD). However, whether this changes with increasing severity NAFLD remains uncertain. We performed meta-analysis observational studies to quantify the magnitude incident CKD. Design systematically searched PubMed, Web Science Scopus from January 2000 August 2020 using predefined keywords identify follow-up duration ≥1 year, in which was diagnosed by blood biomarkers/scores, International Classification Diseases codes, imaging techniques or biopsy. Data selected were extracted, random-effects modelling. Results 13 1 222 032 individuals (28.1% NAFLD) 33 840 cases CKD stage ≥3 (defined as estimated glomerular filtration rate <60 mL/min/1.73 m 2 , without accompanying overt proteinuria) over median 9.7 years included. associated moderately (n=10 studies; HR 1.43, 95% CI 1.33 1.54; I =60.7%). All risks independent age, sex, obesity, hypertension, diabetes other conventional factors. Sensitivity analyses did not alter these findings. Funnel plot reveal any publication bias. Conclusion This large updated indicates that is significantly a~1.45-fold long-term ≥3. Further are needed examine

Language: Английский

---

MAFLD and risk of CKD

Metabolism, Journal Year: 2020, Volume and Issue: 115, P. 154433 - 154433

Published: Nov. 16, 2020

Language: Английский

---

Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review

Frontiers in Medicine, Journal Year: 2019, Volume and Issue: 6

Published: Sept. 13, 2019

According to the World Health Organization, cardiovascular disease (CVD) remains leading cause of death worldwide, accounting for approximately 18 million deaths per year. Nevertheless, worldwide prevalence metabolic diseases, such as type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver (NAFLD), also known be common risk factors CVD, have dramatically increased over last decades. Chronic alcohol consumption is a major chronic diseases (CLD) well being health care cost expenditure spending tremendous amounts money annually. NAFLD has become one plaguing world while standing most in Western countries by representing about 75% all CLD. Currently, CVD. Several been suggested responsible associating (FLD) with CVD through several mechanisms including low-grade systemic inflammation, oxidative stress, adipokines, endoplasmic reticulum lipotoxicity microbiota dysbiosis which may influenced other genetic epigenetic variations. Despite this evidence, exact how FLD can causally contribute are not fully elucidated much unknown. Moreover, current literature supports increasing evidence (CV) adverse events coronary artery disease, subclinical atherosclerosis risk, structural alterations mainly left ventricular hypertrophy, epicardial fat thickness, valvular calcifications aortic valve sclerosis mitral annular calcification functional cardiac modifications diastolic dysfunction addition arrhythmias atrial fibrillation arrythmias conduction defects atrioventricular blocks bundle branch blocks. Patients should evaluated managed accordingly order prevent further complications. Possible management methods include non-pharmacological strategies life style modifications, pharmacological therapies surgical management. This review aims summarize state knowledge regarding pathophysiological linking an CV associated modalities.

Language: Английский

---